Journal of pain & palliative care pharmacotherapy
-
Queries from European physicians about analgesic pharmacotherapy and responses from the author are presented. The topics addressed are tolerance to opioid side-effects, use of botulinum toxin A in pain management, use of ketamine in pain management, opioid addicts' perception of pain, intra-articular injections following joint surgery, and opioid rescue doses for breakthrough pain.
-
Pharmacotherapy for which there is evidence of efficacy in neuropathic pain management is described. The role of opioids is discussed in the context of recent controlled trials. Evidence to support combination pharmacotherapy for neuropathic pain management is presented.
-
On September 13, 2007, the United States Food and Drug Administration posted a safety alert for fentanyl buccal tablets (Fentora). The announcement and hyperlinks to the Dear Doctor and Dear Healthcare Professional Letters that were distributed by the sponsor are presented.
-
J Pain Palliat Care Pharmacother · Jan 2008
Biofeedback in pain management: Bier blocks for complex regional pain syndrome.
This feature presents information for patients in a question and answer format. It is written to simulate actual questions that many pain patients ask and to provide answers in a context and language that most pain patients will comprehend. Issues addressed in this issue are the role of the biofeedback in pain management and Bier blocks for complex regional pain syndrome.
-
J Pain Palliat Care Pharmacother · Jan 2008
The NIH Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT).
Americans continue to spend millions of dollars annually on glucosamine and chondroitin for symptoms of osteoarthritis. These agents are classified as dietary supplements, not as drugs, per se. Therefore, they do not meet the requirements of the FDA to be classified as drugs. ⋯ For a subset of participants with moderate-to-severe pain, glucosamine combined with chondroitin sulfate provided statistically significant pain relief compared with placebo, about 79% had a 20% or greater reduction in pain versus about 54% for placebo. According to the researchers, because of the small size of this subgroup these findings should be considered preliminary and need to be confirmed in further studies. For participants in the mild pain subset, glucosamine and chondroitin sulfate together or alone did not provide statistically significant pain relief.